BioLife Solutions, Inc. (BLFS)

Market Cap	1.16B
Revenue (ttm)	87.76M
Net Income (ttm)	-10.41M
Shares Out	47.56M
EPS (ttm)	-0.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	231,956
Open	24.07
Previous Close	23.29
Day's Range	23.80 - 24.53
52-Week Range	17.15 - 29.55
Beta	2.01
Analysts	Strong Buy
Price Target	30.57 (+25.85%)
Earnings Date	May 8, 2025

About BLFS

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduc...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Nov 22, 1989
• Employees: 159
• Stock Exchange: NASDAQ
• Ticker Symbol: BLFS
• Website: https://www.biolifesolutions.com

Financial Performance

In 2024, BioLife Solutions's revenue was $82.25 million, an increase of 8.44% compared to the previous year's $75.86 million. Losses were -$20.18 million, -70.32% less than in 2023.

Analyst Forecast

According to 7 analysts, the average rating for BLFS stock is "Strong Buy." The 12-month stock price forecast is $30.57, which is an increase of 25.85% from the latest price.

Price Target

$30.57

(25.85% upside)

Analyst Consensus: Strong Buy